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Abstract Like other microorganisms, free-living Can-
dida albicans is mainly present in a three-dimensional
multicellular structure, which is called a biofilm, rather
than in a planktonic form. Candida albicans biofilms can
be isolated from both abiotic and biotic surfaces at various
locations within the host. As the number of abiotic
implants, mainly bloodstream and urinary catheters, has
been increasing, the number of biofilm-associated blood-
stream or urogenital tract infections is also strongly
increasing resulting in a raise in mortality. Cells within a
biofilm structure show a reduced susceptibility to specific
commonly used antifungals and, in addition, it has recently
been shown that such cells are less sensitive to killing by
components of our immune system. In this review, we
summarize the most important insights in the mechanisms
underlying biofilm-associated antifungal drug resistance
and immune evasion strategies, focusing on the most recent
advances in this area of research.
Keywords Candida albicans  Biofilm  Drug
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Introduction
Being a commensal, Candida albicans is expected to
inhabit the urogenital and gastrointestinal tract of a large
percentage of the human population. In healthy individuals,
its growth is confined by actions of the immune system and
by the presence of other commensal microorganisms
occupying its potential niche. However, when one of these
barriers is disrupted, C. albicans can behave as a pathogen
causing both superficial and systemic infections, the latter
with possible infections of internal organs (Berman and
Sudbery 2002; Kim and Sudbery 2011). Bloodstream
infections are associated with considerable attributable
mortality rates varying from 30 to 70 % (Bouza et al. 2013;
Falagas et al. 2006; Kibbler et al. 2003; Peng and Lu 2013;
Wey et al. 1988; Wisplinghoff et al. 2004) and high health-
care costs with estimates ranging from millions to 1 billion
dollars in the US alone (Miller et al. 2001; Wilson et al.
2002). Major risk factors for candidemia are neutrophil
depletion and gastrointestinal damage, resulting in disper-
sion of Candida cells resident in the gastrointestinal tract to
the bloodstream (Koh et al. 2008) and the frequent use of
catheters in hospitalized patients that can present a sub-
strate for the formation of biofilms (Darouiche 2004; Kim
and Sudbery 2011; Kojic and Darouiche 2004). The risk of
biofilm development on catheters has been estimated to be
up to 30 %, depending on the location of the catheter
(Ramage et al. 2006).
Biofilm lifestyle of Candida albicans
Biofilms are defined as structured microbial communities
that are attached to a surface and surrounded by a self-
produced extracellular matrix (Costerton et al. 1995). In the
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early years, major focus was on bacterial biofilms, with a
first model to study C. albicans biofilm development
in vitro only emerging in 1994 (Hawser and Douglas
1994). Since then, ample model systems for the study of
fungal biofilms have been developed (Tournu and Van
Dijck 2012) and C. albicans biofilm formation has been
characterized both in vitro and in vivo by several research
groups (Andes et al. 2004; Chandra et al. 2001a, 2011;
Rˇicˇicova´ et al. 2010). In general, C. albicans biofilm for-
mation is characterized by four stages: (1) cell-wall pro-
tein-mediated adherence of yeast cells to a surface, (2)
growth of the attached yeast cells into a thin layer of cells,
(3) maturation of the biofilm through development of
pseudohyphae and hyphae and excretion of matrix material
and (4) dispersal of yeast cells from the biofilm possibly
leading to colonization of distant places (Blankenship and
Mitchell 2006; Chandra et al. 2001a; Kaneko et al. 2013;
Uppuluri et al. 2010). Although biofilm structures can
differ depending on the growth conditions (Baillie and
Douglas 1998, 2000) mature C. albicans biofilms, mostly
present after 24–48 h of biofilm formation (Andes et al.
2004; Kaneko et al. 2013; Rˇicˇicova´ et al. 2010), consist of
a thin yeast layer responsible for attachment of the thicker
layer, comprising both yeast and hyphal cells, to the sur-
face (Baillie and Douglas 1999b). Structurally, several
microcolonies can be distinguished which are separated by
water channels allowing circulation of nutrients (Douglas
2003; Watnick and Kolter 2000). Over the past years, the
genetic network controlling biofilm formation has been
investigated and partially elucidated, both in vitro and
in vivo (Banerjee et al. 2013; Bonhomme et al. 2011;
Fanning et al. 2012; Garcı´a-Sa´nchez et al. 2004; Murillo
et al. 2005; Nett et al. 2009; Nobile et al. 2012). Discussion
of the genetic control of biofilm formation is not the pur-
pose of this review, but has been discoursed elsewhere
(Finkel and Mitchell 2011; Fox and Nobile 2012; Nobile
and Mitchell 2006).
Although C. albicans is still considered the most pre-
valent pathogen within the Candida clade, non- albicans
Candida species are increasingly being isolated from
patients, with C. glabrata, C. parapsilosis and C. tropi-
calis being the most represented ones (Horn et al. 2009;
Peng and Lu 2013; Pfaller and Diekema 2007, 2010). Like
C. albicans, these species are capable of forming biofilms
(Hawser and Douglas 1994; Shin et al. 2002; Silva et al.
2010), be it to a lesser extent, increasing their potential to
cause disease in patients with medical implant devices.
Next to single species bloodstream infections associated
with biofilms on medical implant devices, multi-species
candidemia is also encountered, making up 4–8 % of all
Candida-associated bloodstream infections (Klotz et al.
2007; Nace et al. 2009). Seemingly more prevalent with
7–27 % of all candidemias are polymicrobial bloodstream
infections, in which Candida spp. are present together
with bacteria such as Enterococcus spp., Streptococcus
spp., Staphylococcus aureus and Pseudomonas aeruginosa
(Bouza et al. 2013; Harriott and Noverr 2010; Klotz et al.
2007).
Biofilms are often regarded as survival mechanisms of
microorganisms since it has been repeatedly shown that
cells associated with biofilms are much less susceptible to
antimicrobial agents such as antibiotics. This was first
shown for bacterial species, with an increase of dosage
ranging from 10- to 100-fold, depending on bacterium and
antibiotic, necessary for the eradication of biofilm-associ-
ated bacteria (Donlan and Costerton 2002). Later, a similar
trend was observed for fungal biofilms with drug concen-
trations needed for a 50 % reduction of metabolic activity
being 5–8 times higher in biofilms compared to planktonic
cells and minimum inhibitory concentrations (MICs)
increasing 30- to 20,000-fold (Hawser and Douglas 1995).
These findings were confirmed on different substrates and
for different Candida spp. (Baillie and Douglas 1999a;
Chandra et al. 2001a; Lewis et al. 2002; Ramage et al.
2001a, b).
Interestingly, Yi et al. (2011b) discovered recently that
C. albicans biofilms formed by MTL (for mating type
locus)-heterozygous cells differed significantly in per-
meability and drug resistance from their MTL-homozy-
gous counterparts. The viability of cells within a/a
biofilms was ninefold greater than that of cells in a/a and
a/a biofilms after challenge of mature biofilms with
24 lg/ml fluconazole during 24–48 h. Moreover, poly-
morphonuclear leukocytes (PMNs) could only impregnate
the upper 11 % of mature biofilms of the a/a-type,
whereas they could penetrate the total volume of MTL-
homozygous biofilms. The researchers propose that the
MTL-heterozygous biofilms form the traditional, protec-
tive biofilm environment mostly found in nature and
causing disease in patients, since 90 % of the free-living
C. albicans cells are heterozygous at their mating type
locus, whereas MTL-homozygous biofilms form a more
penetrable environment which may facilitate mating (Yi
et al. 2011b). Earlier, the same group had already shown
that biofilms of white a/a cells were thinner than MTL-
heterozygous biofilms, and that this could be countered
by addition of a few opaque cells. In nature, it is
expected that a few white cells would spontaneously
switch and function as a source of pheromone of the
opposite mating type, namely the product of MFa (Yi
et al. 2011a).
Since the discovery of high drug resistance conferred
by C. albicans biofilms, several mechanisms underlying
this high antibiotic tolerance have been proposed, and
these are reviewed here together with the latest advances
in the field.
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Resistance to antifungals. What are the underlying
reasons?
The search for safe, cheap and effective antifungals is
being hindered by the great similarities between fungal cell
structure and biosynthesis pathways and their mammalian
counterparts. Current therapies against fungal diseases fall
into five classes: (1) polyenes that bind sterols in the fungal
cell membrane and cause electrolyte leakage via formation
of transmembrane channels, (2) pyrimidine analogs that get
incorporated in a growing RNA/DNA strand and thereby
arrest fungal DNA and RNA synthesis, (3) azoles that
target ergosterol biosynthesis via blockage of the enzyme
lanosterol 14a-demethylase, (4) allylamines that target
ergosterol biosynthesis through blocking of the enzyme
squalene oxidase and (5) echinocandins that block the
enzyme b-1,3-glucan synthase and thereby inhibit incor-
poration of b-1,3-glucans in the cell wall disturbing the
integrity of the cell wall (Cowen and Steinbach 2008;
Denning and Hope 2010; Ostrosky-Zeichner et al. 2010).
For the treatment of biofilms, efficacy of echinocandins
and of the polyene amphotericin B lipid formulations has
been shown both in vitro (Bachmann et al. 2002; Kuhn et al.
2002; Ramage et al. 2002b, 2013) and in vivo (Kucharicova´
et al. 2010, 2013; Mukherjee et al. 2009). The azole anti-
fungal drugs, the pyrimidine analogs, allylamines and
classic formulations of polyenes are not active against
biofilms (Chandra et al. 2001a, b; Hawser and Douglas
1995; Ramage et al. 2001c). In vitro susceptibility of bio-
films to antifungals is generally assessed using the 96-well
microtiter plate-based method first described by Ramage
et al. (2001a) (Pierce et al. 2010). Susceptibility testing
under in vivo conditions is performed using catheter lock
therapies, with amphotericin B, ethanol and echinocandins
showing promising results, (recently reviewed by Walraven
and Lee 2013) or by intraperitoneal or intravenous injection
of drugs to animals that have catheter-related biofilm
infections (Kucharı´kova´ et al. 2010, 2013). The underlying
mechanisms possibly causing the ineffectiveness of the
above-mentioned drugs are described below. To overcome
the inefficacy of these drugs, more and more studies appear
that focus on synergism between antifungals and antibiot-
ics, painkillers etc., resulting in an effective combination
therapy against biofilm-associated C. albicans. Examples of
such therapies include combination of fluconazole and the
tetracycline antibiotic doxycycline (Fiori and Van Dijck
2012; Gao et al. 2013), combination of amphotericin B and
aspirin (Zhou et al. 2012), combination of caspofungin and
the painkiller/anti-inflammation compound diclofenac
(Bink et al. 2012) and the sensitization of C. albicans bio-
films to different antifungals by the immunosuppressant
drug cyclosporine a (Shinde et al. 2012).
Over the course of time a vast amount of research
groups have tried to elucidate the mechanisms underlying
increased resistance in biofilm-associated C. albicans cells.
Some of the proposed causes are shared resistance mech-
anisms between planktonic and biofilm-associated cells
(e.g. upregulation of drug efflux pumps, upregulation of
target gene expression), others are biofilm specific (e.g.
presence of matrix). In what follows, we highlight the
major propositions and recent advances in this field
(Table 1).
Table 1 Resistance mechanisms in Candida albicans
Resistance mechanism Effect In which growth form?
Reduced growth rate Lower presence of antifungal targets, reducing the
antifungal efficacy
Planktonic cells (Baillie and
Douglas 1998)
Cell density Quorum sensing? Common (Perumal et al. 2007;
Seneviratne et al. 2008)
Differential regulation drug targets Changes in target levels, often associated with changes
in target structure rendering the drug incapable of
binding the target (White et al. 1998)
Common (Borecka´-Melkusova´
et al. 2009; Khot et al. 2006;
Nailis et al. 2010; White 1997)
Upregulation drug efflux pumps Antifungal is pumped out of cell and can thereby not
perform its intracellular function
Common (Nett et al. 2009;
Ramage et al. 2002a; Sanglard
et al. 1995, 1997)
Persister cells Because of the dormant state of persisters, antifungal
targets are inactive (Lewis 2010, 2012)
Biofilm (LaFleur et al. 2006)
Presence of a matrix Specific binding of antifungals by b-1,3-glucans, a
major matrix component, which prevents antifungals
from reaching their targets (Nett et al. 2007b)
Biofilm (Al-Fattani and Douglas
2006; Nett et al. 2007b)
Diverse stress responses Possibly only indirect effects via regulation of other
resistance mechanisms (Robbins et al. 2011)
Common (Diez-Orejas et al. 1997;
Kumamoto 2005)
Different mechanisms of resistance have been described, both for planktonic as well as for biofilm cells. In this table we indicate whether the
mechanism is functional in planktonic or biofilm cells or whether the mechanism is common for both life styles
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Reduced growth rate
In general, cells that show a slow growth are more resistant. It
was therefore proposed that biofilm cells are more resistant
because they grow slower. However, the involvement of a
reduced growth rate of biofilm cells for resistance to anti-
fungals was renounced by Baillie and Douglas (1998). They
compared amphotericin B susceptibility of biofilm-associ-
ated C. albicans cells with planktonic cells under different
growth rates. They found that the biofilm-associated cells
were resistant at all growth rates, whereas planktonic cells
were only resistant when showing very slow growth (Baillie
and Douglas 1998). Furthermore, Chandra et al. (2001a)
showed a correlation between metabolic activity and anti-
fungal resistance in maturing biofilms, further invalidating
the effect of growth rate. Lastly, the most common used
assay for quantitatively measuring biofilm formation relies
on the conversion of 2,3-bis-(2-methoxy-4-nitro-5-sulfo-
phenyl)-5-[(phenylamino)carbonyl]-2H-tetrazoliumhy-
droxide (XTT) to a colored formazan in the presence of
metabolic activity (Kuhn et al. 2003; Paull et al. 1988). It is
shown that the formazan signal corresponds very well with
cell number (Hawser 1996) and generally the signal increa-
ses when a biofilm grows (Lal et al. 2010).
Cell density
Based on the fact that the resistance of biofilms changes
with (extreme) inoculum size, Perumal et al. (2007) pro-
posed the influence of cell density on C. albicans drug
resistance. They tested the efficacy of different azoles,
amphotericin B and the echinocandin caspofungin on
planktonic cells at densities similar to those found in bio-
films (up to 1 9 108 cells/ml) and showed that at high cell
densities planktonic cells had markedly reduced suscepti-
bilities to all drugs. These results seemed not to be asso-
ciated with drug efflux or farnesol quorum sensing since a
strain deficient in these mechanisms showed the same
trend. Moreover, the susceptibility of dissociated biofilm
cells diluted to 1 9 103 cells/ml was similar to that of
planktonic cells at the same cell density, indicating that the
increased resistance was indeed associated with the biofilm
architecture. Similar conclusions were obtained by Sene-
viratne et al. (2008) for the azole ketoconazole and the
pyrimidine analog 5-flucytosine. However, they did not see
a density-dependent susceptibility of planktonic or biofilm-
associated cells to both caspofungin and amphotericin B,
but they account the modified experimental procedures
responsible for these discrepancies.
Therefore, cell density does seem to have an effect on C.
albicans resistance to several drugs, but this is probably not
a biofilm-specific resistance mechanism since a similar
trend was observed in planktonic cells.
Altered gene expression
Upregulation of specific genes has been shown to be
involved in antifungal drug resistance in planktonic cells
(Sanglard 2002; White et al. 1998). These genes can vary
from genes encoding efflux pumps such as CDR1 and
MDR1 (Sanglard et al. 1995; White 1997), which will be
discussed later, to genes encoding the protein targets of
antifungals such as genes involved in the ergosterol bio-
synthesis pathway (White 1997). The latter will cause
changes in target levels, often associated with altered target
structure, both resulting in the inability of the drug to
effectively eradicate the pathogen (White et al. 1998). It is
therefore plausible that alterations in gene expression are
also responsible for drug resistance in biofilm-associated C.
albicans cells. In this regard, expression levels of genes
encoding proteins involved in the production of cell
membrane and cell-wall components have been a major
point of focus, with the genes involved in the ergosterol
biosynthesis pathway being the most studied ones.
In a first study, mRNA levels of genes involved in
ergosterol biosynthesis (the ERG-genes) and in b-1,6-glu-
can biosynthesis (SKN1 and the KRE-genes) were deter-
mined via quantitative RT-PCR and compared between
planktonic and biofilm-associated cells (Khot et al. 2006).
The researchers found a unique transcript profile in a
subpopulation of amphotericin B-resistant blastospores
with a significant downregulation of ERG1 and a signifi-
cant upregulation of ERG25, SKN1 and KRE1. Transcrip-
tion levels of the latter gene also showed a correlation with
increasing resistance at higher concentrations of ampho-
tericin B. Later, the changes in ERG-gene expression upon
addition of the azole fluconazole were investigated by
Borecka´-Melkusova´ et al. (2009) using reverse transcrip-
tase and real-time PCR in different C. albicans isolates.
They found upregulation of ERG9 regardless of the sus-
ceptibility of the tested strains to fluconazole and down-
regulation of ERG11 in fluconazole-susceptible strains, the
product of the latter being the target of the azole class of
antifungals. Detailed analysis of ERG1 and ERG25
expression upon addition of fluconazole showed slight
increases in gene expression in both planktonic and bio-
film-associated cells. A study by Nailis et al. (2010)
showed a drug-specific transcription response upon chal-
lenge of biofilms with high concentrations of antifungals.
They challenged biofilm-associated C. albicans cells with
high doses of fluconazole and amphotericin B and analyzed
gene expression profiles using quantitative RT-PCR. They
noticed significant increases in ERG1, ERG3, ERG11 and
ERG25 in mature biofilms upon addition of fluconazole
and significant increases in SKN1, KRE1 and ERG1 in
mature biofilms upon challenge with amphotericin B. The
results of these three studies show that possible differential
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regulation of gene expression within biofilm-associated
cells is very much depending on the experimental setup.
Recently, Yu et al. (2012) found that mature biofilms
grown in the presence of farnesol, which is the precursor of
ergosterol and a quorum-sensing molecule in C. albicans,
showed a significant increase in fluconazole susceptibility
compared to a farnesol-untreated biofilm. Using RT-PCR,
they could show that transcription levels of ERG1, ERG3,
ERG6, ERG11 and ERG25 decreased significantly in the
farnesol-treated group, indicating that the ergosterol bio-
synthesis pathway may contribute to the inhibitory effect of
farnesol and further arguing that increased transcription of
the ERG-genes does increase biofilm resistance.
A whole transcriptome approach was applied by Vedi-
yappan et al. (2010), who challenged mature biofilms during
2 h with fluconazole, amphotericin B and caspofungin in
concentrations that were lethal for planktonic cells but not
for biofilm-associated cells. Upon addition of fluconazole,
only five genes were differentially expressed, causing the
researchers to put forth that biofilm-associated cells might be
blind to fluconazole, also explaining its inefficacy. Upon
addition of amphotericin B, they saw a differential expres-
sion of 160 genes, whereas upon challenge with caspofungin
the amount of differentially expressed genes increased up to
a couple of hundred genes. Interestingly, this shows a cor-
relation between antifungal susceptibility and the amount of
differentially expressed genes, which is a trend opposite to
what would be expected if genetic alterations are the main
reason for antifungal resistance in biofilms.
An apparent contradiction rises from the studies cited
here above and we want to stress that this might reflect a
highly model-dependent mechanism since the in vitro
model systems for biofilm formation utilized in the cited
studies differed. It is for example known that the presence
of medium flow during the formation of biofilms signifi-
cantly alters the biofilm structure (Al-Fattani and Douglas
2006; Baillie and Douglas 2000; Hawser et al. 1998) and
that the resistance to commonly used antifungals of bio-
films grown under flow conditions differs significantly
from statically grown biofilms (Uppuluri et al. 2009, 2011).
It is therefore possible that the experimental setup for
biofilm formation also influences differential gene expres-
sion in biofilm-associated cells upon challenge with anti-
fungals, which would mean that this resistance mechanism
is highly model dependent. For this reason, we do not
expect altered expression of genes encoding antifungal
targets to be the major resistance mechanism in biofilm-
associated cells.
Upregulation of drug efflux pumps
Upregulation of drug efflux pumps has been described as a
causative factor in biofilm drug resistance for several
biofilm-forming microorganisms (Soto 2013). In C. albi-
cans, two groups of efflux pumps have been shown to
contribute to drug resistance: the ATP binding cassette
(ABC) transporters encoded by the CDR-genes and the
major facilitator (MF) superfamily encoded by the MDR-
genes (Ben-Yaacov et al. 1994; Fling et al. 1991; Marger
and Saier 1993; Prasad et al. 1995).
An increased expression of CDR1 (for Candida drug
resistance) and MDR1 (for multidrug resistance; also
known as BENr for benomyl resistance) was first docu-
mented by Sanglard et al. (1995), in C. albicans clinical
isolates with a high azole resistance associated with pro-
longed treatment. Moreover, this group showed that
mutants lacking CDR1 and MDR1 lost their azole resis-
tance together with resistance to other antifungals and
metabolic inhibitors (Sanglard et al. 1996). Upregulation of
these genes was confirmed by White (1997), and in addi-
tion they showed that members of the other families
making up the ABC transporters were not involved in
increased drug efflux. Later, Sanglard et al. (1997) identi-
fied a second member of the ABC transporter family,
encoded by CDR2, which could rescue drug resistance in
the highly susceptible S. cerevisiae multidrug transporter
pdr5D mutant. Northern blotting performed on total RNA
showed an increased expression of CDR2 in resistant C.
albicans strains. The involvement of a second member of
the MF superfamily, encoded by FLU1 (for fluconazole
resistance), was discovered by usage of the same S. cere-
visiae pdr5D mutant (Calabrese et al. 2000). So far, no
other genes have been shown to be involved in this process.
Efflux pump upregulation seems to primarily play a role in
azole resistance (Mateus et al. 2004; Mukherjee et al. 2003;
Ramage et al. 2002b; Sanglard et al. 1996) and is reported
not to be involved in echinocandin resistance (Niimi et al.
2006).
An induced expression of CDR1, CDR2, MDR1 and
FLU1 in biofilm-associated C. albicans cells compared to
planktonic cells has been shown both in vitro (Mateus et al.
2004; Mukherjee et al. 2003; Ramage et al. 2002b) and
in vivo (Andes et al. 2004; Nett et al. 2009). Increased
expression of the CDR-genes was mainly observed after
24 h and to a lesser extent after 48 h, while MDR1 was
solely overexpressed after 24 h (Mukherjee et al. 2003;
Ramage et al. 2002a). These observations already indicate
that upregulation of drug efflux pumps does not play a
major role in drug resistance in mature biofilms because
both groups observed a decrease in efflux pump gene
expression in aging biofilms whereas generally resistance
increases as the biofilm ages. In fact, it seemed like chal-
lenge of the biofilm with antifungals was not necessary
since adherence to a surface was enough to trigger this
gene overexpression (Lepak et al. 2006; Mateus et al.
2004). Moreover, several studies have shown that CDR1,
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CDR2 and MDR1 single and double mutants are suscepti-
ble to azoles when grown planktonically despite retaining
their resistance when grown in a biofilm structure, thereby
implying that the presence of these genes is not necessary
for resistance in biofilms (Mukherjee et al. 2003; Perumal
et al. 2007; Ramage et al. 2002a).
Recently, it was discovered that the efflux pump enco-
ded by FLU1 is also responsible for efflux of the salivary
human antimicrobial peptide histatin 5 (Hst5) that is toxic
to C. albicans. Li et al. (2013) showed that flu1D/D had
significantly reduced efflux rates of Hst5 and significantly
higher cytosolic Hst5 concentrations. Moreover, this
mutant showed reduced biofilm formation capacity in the
presence of Hst5. RT-PCR of C. albicans cells showed that
FLU1 expression levels did not increase upon challenge
with Hst5 in the short term, giving an indication that
FLU1-upregulation is unlikely to become a mechanism for
resistance against Hst5, showing its therapeutic potential.
In conclusion, although an increased expression of genes
encoding efflux pumps has been observed in the early
hours of biofilms formation, this does not seem to be the
case in mature biofilms. Moreover, it has been shown that
mutants lacking genes encoding efflux pumps still retain
their resistance to antifungals when grown in a biofilm.
These observations lead to the conclusion that upregulation
of drug efflux pumps is not a major cause for increased
resistance of biofilm-associated cells.
Persister cells
Persister cells are phenotypic variants rather than mutants
(Keren et al. 2004; LaFleur et al. 2006) that are able to
survive antibiotic concentrations well above MICs (LaFl-
eur et al. 2006). It is thought that the inability of an anti-
biotic to eradicate persister cells is a consequence of the
dormant state in which persister cells are present, since
antibiotics need an active target to perform their function
(Lewis 2010, 2012).
Since the discovery of persister cells in 1944 (Bigger
1944), their presence has been shown in biofilms formed by
different bacterial species such as P. aeruginosa and
Escherichia coli (Harrison et al. 2009; Spoering and Lewis
2001) in which they make up 0.1–1 % of all cells (Keren
et al. 2004). The presence of persister cells in Candida
biofilms was first shown in 2006 when LaFleur et al. (2006)
observed a biphasic killing of C. albicans biofilms, with the
majority of the population being killed at relatively low
amphotericin B concentrations and a very small fraction of
cells remaining resistant even at high concentrations of the
drug. 1 % of the population was completely unharmed by
antifungal agents, and these cells were appointed ‘‘per-
sisters’’. Moreover, the group showed that the presence of
persisters was not dependent on the formation of a complex
biofilm structure, but rather on the ability to attach to a
surface.
Blocking persister survival can be an interesting thera-
peutic option aiming at increasing C. albicans biofilm
susceptibility to antifungals. Bink et al. (2011) discovered
that superoxide dismutases, encoded by SOD-genes in
C. albicans and important for detoxification of reactive
oxygen species (ROS), play a major role in miconazole
persistence through upregulation of SOD-genes upon
addition of miconazole. By addition of a superoxide dis-
mutase inhibitor N,N’-diethyldithiocarbamate (DDC) to
C. albicans biofilms, they reduced the miconazole-resistant
persister fraction 18-fold.
However, quickly after the discovery of persisters in
Candida biofilms, it was shown that not all Candida strains
produce persister cells (Al-Dhaheri and Douglas 2008).
When the effect of AmB on biofilm formation by two C.
albicans strains, namely SC5314 and GDH 2346, was
tested, it was demonstrated that biofilms formed by the
latter strain contained a small amount of cells that was
resistant to AmB concentrations of 100 lg/ml after 24 h of
exposure whereas the MIC for planktonic cells of this
strain is 1.3 lg/ml. Surprisingly, however, biofilms formed
by SC5314 showed no cells surviving after the same
treatment. These results were later confirmed by a life-dead
staining of biofilms cells exposed to 100 lg/ml AmB using
fluorescein diacetate (Al-Dhaheri and Douglas 2010). As a
consequence of these findings it can be concluded that the
presence of persisters cannot be the only reason for drug
resistance in C. albicans biofilms.
Matrix
Cells within a C. albicans biofilm are embedded in an
extracellular self-produced matrix (Costerton et al. 1995).
The amount of matrix material present depends on the
growth conditions to which the biofilm is subjected, with
much more matrix material being produced when the cells
are confronted with a liquid flow as compared to static
conditions (Hawser et al. 1998). Like extracellular poly-
meric material produced by planktonic cells, the main
components of the biofilm matrix are carbohydrates (glu-
cose, mannose, rhamnose and N-acetylglucosamine), pro-
teins, phosphorus, uronic acid and hexosamine (Al-Fattani
and Douglas 2006; Lal et al. 2010). However, when com-
paring the exact composition of biofilm matrix material
with its counterpart produced by planktonic cells, consid-
erate differences were discovered concerning its carbohy-
drate and protein content indicating that there might be
some features specific to biofilm matrix material (Al-Fat-
tani and Douglas 2006; Baillie and Douglas 2000; Hawser
et al. 1998). Recently, it was discovered that extracellular
DNA (eDNA) is also an important component of biofilm
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matrix material, with amounts increasing over time, and
that treatment with deoxyribonuclease I (DNAse) decreases
biofilm biomass at later time points (Martins et al. 2010).
Moreover, DNAse could enhance the activity of AmB and
caspofungin on C. albicans cells in mature biofilms. Such a
synergy was not observed with fluconazole (Martins et al.
2012).
To determine whether the presence of matrix material
indeed increases the resistance of biofilms to antifungal
products, Al-Fattani and Douglas (2006) grew C. albicans
biofilms under static conditions, resulting in a small
amount of matrix material, and under conditions of con-
tinuous flow using a modified Robbins device (MRD).
Using scanning electron microscopy (SEM), they could
confirm the presence of much more matrix material in the
biofilms grown under continuous flow, compared with
biofilms grown statically, as was expected. When chal-
lenging mature biofilms grown under both conditions with
5- and 30-times the MIC for planktonic cells, they found
that biofilm resistance was correlated with the amount of
matrix material present. In contrast, two earlier publica-
tions that compared drug susceptibility of statically grown
biofilms with biofilms grown under gentle shaking did not
report any differences associated with the extent of matrix
formation (Baillie and Douglas 2000; Hawser et al. 1998).
This might be caused by the difference in flow regimen
(Al-Fattani and Douglas 2006), with the MRD, which
causes a continuous unidirectional flow over the surface,
possibly mimicking natural conditions more than does
gentle shaking.
One potential mechanism by which matrix material
increases biofilm resistance is via restricting penetration of
the drug through the biofilm. This was, however, quickly
confuted when Al-Fattani and Douglas (2004) showed that
unless their observation that diffusion rates differed for
different drugs, after 3–6 h of drug exposure, distal places
in the biofilm showed drug concentrations that were several
times the MICs. Even with this drug permeability into the
biofilm, complete killing of biofilm-associated cells could
not be accomplished.
A new light was shed on the matter when Nett et al.
(2007b) discovered that cell walls of biofilm-associated
cells were up to two times thicker and contained more
carbohydrates and b-1,3-glucans than stationary or log-
phase planktonic cells. This was true both in vitro, with
supernatant of biofilms containing two to tenfold more b-
1,3-glucans than supernatant of planktonic cells, and
in vivo, with serum of rats with a biofilm-associated
infection on a central venous catheter containing nearly
tenfold more b-1,3-glucans than serum of rats with dis-
seminated candidiasis. After isolation of matrix material,
they could also show the presence of b-1,3-glucans in the
biofilm matrix, and this amount was shown to increase over
the course of biofilm maturation (Nett et al. 2010). More-
over, they were able to show that biofilm-associated cells
could bind four to fivefold more fluconazole per cell-wall
weight compared to the planktonic cells. Combining these
two observations seems to indicate that b-1,3-glucans bind
fluconazole in biofilm structures, thereby decreasing its
potential to control biofilm-associated cells. To further
support this hypothesis it was shown that both in vitro and
in vivo, a combination of 1,000 lg/ml fluconazole with
1.25 units/ml zymolyase (a glucanase) could decrease
biofilm viability, whereas either one separately was not
able to do so (Nett et al. 2007a, b). Addition of fluconazole
to biofilms at concentrations reducing metabolic activity
was shown not to alter exopolysaccharide material and
biofilm architecture (da Silva et al. 2012), giving an indi-
cation that binding of fluconazole to b-1,3-glucans will not
affect matrix material or biofilm structure. Specific binding
of antifungals by b-1,3-glucans was later shown for AmB
(Vediyappan et al. 2010). Recently, Mitchell et al. (2013)
showed that also in non-albicans Candida species, b-1,3-
glucans contribute to azole resistance by specific binding.
Since this discovery, the involvement of different genes
in this process has been elucidated. Firstly, the gene FKS1,
encoding a b-1,3-glucan synthase which is the target for the
echinocandin class of antifungals, was shown to be nec-
essary for resistance, since viability of cells in a biofilm
produced by a heterozygous deletion mutant which showed
a 30 % reduction in b-1,3-glucans content, was reduced
with 80 % after 48 h of treatment with 250 lg/ml fluco-
nazole. A similar effect was not observed in planktonic
cells (Nett et al. 2010). Furthermore, genes involved in the
protein kinase C cell-wall integrity pathway, which con-
trols cell-wall glucan content in response to stress, namely
SMI1 and RLM1, were shown to be essential for C. albi-
cans matrix and cell-wall b-1,3-glucan content (Nett et al.
2011). Moreover, Taff et al. (2012) showed that two pre-
dicted glucan transferases, encoded by BGL2 and PHR1,
and one exoglucanase XOG1, which are predicted to be
present in the extracellular matrix, are crucial for b-1,3-
glucans delivery to the matrix and accumulation of b-1,3-
glucans in matrix material, with biofilm-associated mutants
lacking these genes showing an increased susceptibility to
fluconazole. Similar phenotypes were not observed for
planktonic cells. Since b-1,3-glucans are also a major
component of the cell wall, the researchers propose that the
three above-mentioned glucan modification proteins are
also present in the cell wall. Lastly, research by Yi et al.
(2011b) showed that biofilm regulation, including matrix
deposition, in strains with a differential MTL-locus con-
figuration involves a different pathway and different tran-
scription factors. The more resistant MTL-heterozygous
biofilms are regulated by the Ras1/cAMP pathway and
require the subsequent action of transcription factors
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Efg1p, Tec1p and Bcr1p, which were termed the ‘‘tran-
scription factor cascade’’. On the other hand, the structur-
ally similar but thinner and more permeable MTL-
homozygous biofilms are regulated by the mitogen-acti-
vated protein kinase (MAPK) pathway and are so far only
shown to require the action of transcription factor Tec1p.
Most interestingly, these observations might indicate the
importance of regulation of matrix deposition over general
biofilm architecture in conferring antifungal resistance, but
further research is needed to validate this proposition.
Whereas binding of several antifungals by b-1,3-glucans
that make up a big part of C. albicans biofilm matrix
material has been proven to reduce antifungal susceptibility
of biofilm-associated cells, this cannot be the only reason
for increased drug resistance in biofilms. In the first paper
describing resistance of C. albicans biofilms (Hawser and
Douglas 1995), they were grown under static conditions
meaning that they contain much less matrix material than
they would do in vivo where they are constantly exposed to
fluid motion (Hawser et al. 1998; Hawser and Douglas
1995).
Stress responses
During colonization of its host, C. albicans is confronted
with a wide variety of stresses to which it responds via
different conserved signal transduction pathways of which
the MAPK network is a crucial component (Cannon et al.
2007; Monge et al. 2006). An important part of the MAPK
network is the protein kinase C cell-wall integrity pathway
that signals via the MAPK Mkc1p (Cannon et al. 2007;
Navarro-Garcia et al. 1995, 1998). Whereas the importance
of the cell-wall integrity pathway for virulence in a murine-
disseminated Candida model was already published in
1997 (Diez-Orejas et al. 1997), its importance in normal
biofilm formation and biofilm resistance was not known
until 2005 (Kumamoto 2005) when it was demonstrated
that an mkc1-null mutant formed an abnormal biofilm with
reduced filamentation after 48 h of development. More-
over, biofilms formed by the mkc1-null mutant were sus-
ceptible to MICs 100-fold lower than wild-type and
reintegrant strains.
Another key player in stress responses, the serine/thre-
onine protein phosphatase calcineurin, was already known
to be necessary for survival in serum and therefore for
disseminated infection by C. albicans (Blankenship and
Heitman 2005), when Uppuluri et al. (2008) showed that
Candida strains mutated in calcineurin B (CNB1), which
encodes the catalytic subunit of the protein, or its down-
stream target, the transcription factor Crz1, could be
restricted by much lower fluconazole concentrations than
their wild-type counterparts. In concordance with this, we
have to elaborate on heat shock protein 90 (Hsp90), which
interacts with the catalytic subunit of calcineurin to stabi-
lize it and prepare it for activation (Singh et al. 2009).
Hsp90 is known to be important for C. albicans resistance
against azoles and echinocandins (Singh et al. 2009) and
was shown to be necessary for biofilm dispersal and
resistance to azoles in vitro and in vivo (Robbins et al.
2011). The latter might be caused by the fact that Hsp90 is
a regulator of matrix glucan levels, with deletion of Hsp90
resulting in matrix material with reduced b-1,3-glucans-
levels, and thus a reduced potential to capture antifungals
(Robbins et al. 2011). These results indicate that a com-
bination therapy of an Hsp90 inhibitor or calcineurin
inhibitor, together with fluconazole would be an interesting
therapeutic option. The potential and likelihood of C.
albicans to develop resistance against such a combination
therapy was investigated by Hill et al. (2013). They started
from strains that were resistant to azoles in a manner
dependent on Hsp90 and calcineurin. Of the 290 strains
they started with, 7 C. albicans strains developed resistance
to fluconazole and either geldanamycin (Hsp90 inhibitor)
or FK506 (calcineurin inhibitor). Resistance mechanisms
identified included: drug target mutations that conferred
resistance against geldanamycin and FK506, mutations in a
gene encoding a transcriptional activator of drug efflux
pumps, namely PDR1, mutations that transformed azole
resistance from dependent on calcineurin independent on
this regulator and mutations in the catalytic subunit of
calcineurin. Moreover, they showed extensive aneuploidy
in four of the C. albicans lineages (Hill et al. 2013), a
characteristic that has been shown to increase fitness during
drug resistance development (Selmecki et al. 2009). A
second heat shock protein, Hsp104, was recently shown to
be important for in vitro biofilm formation and virulence in
a Caenorhabditis elegans infection model, but a role for
Hsp104 in biofilm drug resistance was not addressed in this
study (Fiori et al. 2012).
From this it is clear that the high resistance to commonly
used antifungals by biofilm-associated C. albicans cells
cannot be attributed to the actions of just one mechanism,
but is rather a comprehensive mechanism reflecting the
complexity of the biofilm lifestyle itself.
Escape from the immune system
The presence of pathogens in and on our bodies is gener-
ally detected by pattern recognition receptors (PRRs) that
are present on different cells of our innate immune system
and recognize pathogen-associated molecular patterns
(PAMPs) that are either present on the cell wall of the
pathogen or are secreted by the pathogen. Successful
binding of a ligand by PRRs causes receptor-specific sig-
naling through a downstream cascade, which eventually
results in pathogen phagocytosis, the onset of a pro-
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inflammatory response via production of cytokines and
chemokines and secretion of microbicidal compounds
(Seider et al. 2010). The major components of the C.
albicans cell wall, such as b-1,3-glucans, are responsible
for its detection by several specific receptors, the most
important ones belonging to the classes of toll-like recep-
tors (TLRs) and C-type lectin receptors (CLRs) (Bourgeois
et al. 2010; Netea et al. 2008). However, over the course of
time, C. albicans has evolved several immune evasion
strategies resulting in reduced recognition of the pathogen
by our immune system. A couple of these immune evasion
mechanisms include masking of specific cell-wall compo-
nents to prevent PRR-mediated recognition (Galan-Diez
et al. 2010; Wheeler and Fink 2006), secretion of aspartic
proteases to inactivate components of the innate immune
system (Gropp et al. 2009; Meiller et al. 2009), switching
to the opaque form with reduced filamentation to circum-
vent recognition mechanisms based on the hyphal state
(Sasse et al. 2013) and expression of surface proteins such
as Pra1p and Gpd2p that actively bind factor H and FHL1
thereby mimicking host cells resulting in protection from
the complement system (Luo et al. 2009; Luo et al. 2013).
Analysis of the interaction between biofilm-associated
C. albicans cells and our immune system started only
recently but has already shown to be very distinct from
interactions with planktonic C. albicans cells. In their
research, Chandra et al. (2007) showed that peripheral
blood mononuclear cells (PBMCs) did not phagocytose
biofilm-associated cells, as opposed to planktonic cells. In
contrast, the presence of PBMCs during biofilm develop-
ment enhanced the process with significantly thicker bio-
films being formed as a consequence of unknown factors
secreted by the immune cells. Comparable to this, it was
found that the presence of the pro-inflammatory cytokine
IL-17A enhanced C. albicans biofilm formation in vitro
(Zelante et al. 2012). These data support the idea that
biofilm formation might be an adaptation to survival within
the hostile environment inside the host.
By a mechanism that is still unknown, biofilm-associ-
ated C. albicans cells can change the profile of cytokines
secreted by PBMCs (Chandra et al. 2007) and phagocytes
(Katragkou et al. 2010). Furthermore, when biofilms were
exposed to the echinocandin anidulafungin, the cytokine
profile secreted by the phagocytes was altered once more
toward a more beneficial Th1 response (Katragkou et al.
2010) thereby steering our immune system into eradication
of the invasive fungal infection (Kullberg et al. 2004).
Infiltration of immune cells into the biofilm structure has
been reported repeatedly. In in vitro studies, PBMCs and
PMNs were shown only to be present in the top and middle
layers of most biofilms (Chandra et al. 2007; Yi et al.
2011b), whereas the less frequently encountered, more
penetrable MTL-homozygous biofilms possessed PMNs
distributed over their whole volume (Yi et al. 2011b). In an
in vivo mouse model of oropharyngeal candidiasis, clusters
of neutrophils were found to be present in the mucosal
biofilm structure (Dongari-Bagtzoglou et al. 2009).
Reduced activity of innate immune cells on biofilm-
associated C. albicans cells was also shown by Katragkou
et al. (2010). They demonstrated that the potential of
phagocytes to kill C. albicans was reduced for biofilm-
associated cells, compared to planktonic cells and resus-
pended biofilm cells, similar to the above-mentioned
behavior of PBMCs on biofilm-associated cells discovered
by Chandra et al. (2007). Exposing the biofilms to sub-
inhibitory concentrations of anidulafungin (0.12 mg/l) led
to a significant increase in phagocyte induced damage,
which, according to them, might be caused by an increased
exposure of b-1,3-glucans which are important PAMPs.
The hypothesis that cells are primarily protected by mature
biofilms was established by Xie et al. (2012). When 3-h old
biofilms were exposed to HL-60 (a human neutrophil-like
cell line) cells they lost over 80 % of their activity, whereas
the activity of 24- and 48-h biofilms was only reduced with
less than 30 %. Consistent with this, mature biofilms did
not elicit a robust oxidative response, which is one of the
main mechanisms by which neutrophils kill pathogens, in
sharp contrast with 3-h old biofilms. Moreover, dispersed
24-h biofilm cells also failed to prevent a ROS response,
leading the group to suspect a role for the biofilm matrix.
This role was confirmed when biofilm matrix alone did not
trigger a reactive oxygen response, and the true protector
was unmasked when glucanase treatment of the matrix
completely abrogated the matrix ROS-attenuating effect.
Conclusion
Reducing the incidence of biofilm-related candidemias in
hospitals is a requirement in the search for optimized
patient care. However, the high degree of resistance of
biofilm-associated C. albicans cells hinders rapid devel-
opment toward highly efficacious therapies. Recent efforts
of various excellent research groups tremendously broad-
ened our knowledge on the complex mechanisms under-
lying biofilm resistance. According to the authors, the
presence of matrix material is the most important biofilm-
resistance mechanism. Its involvement has been shown by
several elegant experiments and the fact that it is only
present in biofilms can explain the increased susceptibility
of planktonic cells and resuspended biofilm cells. However,
we do expect that several less important mechanisms such
as cell density, differential regulation of drug targets,
upregulation of drug efflux pumps in developing biofilms,
the presence of persisters in biofilms, upregulation of dif-
ferent pathways associated with stress responses and
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possibly yet undefined mechanisms can further increase
resistance to a maximum level. The elucidation of these
resistance mechanisms provides a promising step toward
the development of optimal therapies. Such therapies can
include classic antifungal therapies including catheter lock
therapies, combination therapies, natural compounds (Sardi
et al. 2013) and immunotherapies that are gaining more and
more attention. To enable us to develop the full potential of
immunotherapies, lot of effort is being put in revealing the
specific interaction of biofilm-associated C. albicans cells
with components of our immune system.
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